Advertisement

Person › Details
Veronica Gambillara Fonck (Pureos Partners AG)
Gambillara Fonck, Veronica (Bellevue 202210–Partner at Pureos Partners before GlycoEra + LimmaTech + GlycoVaxyn)
![]() |
Product | vaccine technology |
Product 2 | vaccine | |
Pureos Partners AG. (9/28/22). "Press Release: Pureos Partners Welcomes Dr. Veronica Gambillara Fonck as New Partner to Its Investment Team". Pfäffikon.
Pureos Partners announces the appointment of Dr. Veronica Gambillara Fonck as a Partner to its team, effective 1 October 2022. Veronica is a biotech entrepreneur with more than 15 years of experience in building and growing biotech companies developing new drugs against several diseases. She was one of the core members responsible for building GlycoVaxyn’s success and its acquisition by GSK in 2015, when she became CEO and co-founder of LimmaTech. Subsequently, she was the founder CEO of Glycoera, a biotech spin-off from LimmaTech and successfully financed the company with a large Series A round in November 2021.
Klaus Breiner, Dominik Escher and Martin Münchbach, Managing Partners of Pureos stated: “We are very excited to welcome Veronica as a new Partner at Pureos. As a long-term biotech entrepreneur, she brings deep operational experience to the fund from which many of our portfolio companies will be able to benefit a great deal.”
Veronica commented: “I look forward to joining the Pureos team. The current portfolio of Pureos comprises very exciting biotech companies. I am thrilled to be able to contribute to the expansion of the Pureos franchise, with both the current fund as well as future fund generations”.
###
About Pureos Partners and Pureos Bioventures
Pureos Partners is a Swiss venture capital firm and the investment adviser of Pureos Bioventures. It invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.
For more information visit www.pureosbio.com
Contact
Dr. Klaus Breiner
[email protected]
Dr. Dominik Escher
[email protected]
Dr. Martin Münchbach
[email protected]
Pureos Partners AG
Churerstrasse 47
8808 Pfäffikon/SZ
Switzerland
Record changed: 2024-07-17 |
Advertisement

More documents for Veronica Gambillara Fonck
- [1] Memo Therapeutics AG. (11/02/23). "Press Release: Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients". Schlieren....
- [2] Minervax ApS. (12/15/22). "Press Release: Minervax Announces 72M EUR Financing to Advance Development of Novel Vaccine against Group B Streptococcus". Copenhagen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top